Computational Tools for Research in Neuroscience, Behavioral Science and Mental H

用于神经科学、行为科学和心理健康研究的计算工具

• 批准号: 8550137
• 负责人: GEORGE ZUBAL
• 金额: $ 81.31万
• 依托单位: MOLECULAR NEUROIMAGING, LLC
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8550137
• 关键词: Algorithms; Alzheimer' s Disease; Amyloid beta-Protein; Area; Behavioral Sciences; Biological Markers; Brain; Brain scan; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; Clinics and Hospitals; Computer software; Corpus striatum structure; Data Set; Development; Diagnosis; Discipline of Nuclear Medicine; Disease Progression; Documentation; Evaluation; FDA approved; Generations; Goals; Housing; Human; Image; Image Analysis; Individual; MRI Scans; Manuals; Masks; Medical center; Methods; Monitor; Morbidity - disease rate; Neurologist; Neurosciences; Parkinson Disease; Patients; Pharmacologic Substance; Phase; Physicians; Positron-Emission Tomography; Process; Program Evaluation; Psyche structure; Radio; Reporting; Research; Scanning; Site; Slice; Societies; Solutions; Staging; Suggestion; Supervision; System; Testing; Texas; Tissues; Tracer; Training; Treatment Efficacy; Validation; Work; amyloid imaging; base; clinical application; computerized tools; diagnosis evaluation; disease diagnosis; dopamine transporter; follow-up; gray matter; image processing; improved; pre-clinical; prevent; programs; prospective; radioligand; radiotracer; research clinical testing; research study; single photon emission computed tomography; success; therapy development; tool

DESCRIPTION (provided by applicant): We propose to develop a software package to automatically evaluate a subject's beta amyloid PET scan (using either C11-PIB, F18-florbetaben, or F18-florbetapir, F18-flutemetamol) by normalizing the subject's scan, masking away non-gray matter tissue (without relying on co-registered MRI scans), placing standardized ROIs onto the transverse slices, and reporting SUVr values in separate brain areas referenced to the cerebellar gray matter. Our goal is that this analysis package ultimately would be FDA-510(k) approved and distributed to hospitals and clinics (and pharmaceutical companies), as a commercial product, to aid in the evaluation and diagnosis of patients. Through the use of such a validated and standardized analysis package, new radio-tracers can be objectively compared for their accuracy in quantitating beta amyloid in the brain, and more importantly, new therapies can be objectively and quantitatively evaluated for their efficacy in preventing or removing beta amyloid for each patient, on a personalized individual basis. An important portion of the testing, user interface evaluation, and ADER's report generation utility and clinical application will be conducted in a subaward under the supervision of Dr. Michael Devous within the Nuclear Medicine Center at the UT Southwestern Medical Center, Dallas, Texas. At MNI, New Haven, we will continue to test and evaluate ADER in house within our Radio-tracer Evaluation Program (RTEP) program, where we continue to test potential new beta amyloid PET and SPECT imaging agents, while clinically evaluating subjects by our in-house neurologists and support staff. The potential benefit to society is considerable since an ADER analysis package would provide a quantitative biomarker analysis method for Alzheimer's disease progression for individualized therapy efficacy. Alzheimer's disease (AD) is associated with significant morbidity and a useful marker and/or brain scan analysis package, like this proposed ADER, would add to our understanding of AD disease progression and provide objective assessment of neuroprotective and restorative therapies. This fully automated image processing will also allow for fewer subjects to be studied (with the same clinical power) in clinical trials using new PET and SPECT radioligands. As new tracers and therapies are developed, ADER would co-evolve with these studies into an optimized image analysis method for diagnosing, staging and treating Alzheimer's disease.

描述（申请人提供）：我们建议开发一个软件包来自动评估受试者的β淀粉样蛋白PET扫描（使用C11-PIB、F18-florbetaben或F18-florbetapir、F18-flutemetaben）通过标准化受试者的扫描，掩盖非灰质组织（不依赖于共配准的MRI扫描），将标准化的ROI放置在横向切片上，并报告参考小脑灰质的单独脑区中的SUVr值。我们的目标是，该分析包最终将获得FDA-510（k）批准，并作为商业产品分发给医院和诊所（以及制药公司），以帮助评估和诊断患者。通过使用这种经验证和标准化的分析包，可以客观地比较新的放射性示踪剂在定量脑中β淀粉样蛋白方面的准确性，更重要的是，可以在个性化的个体基础上客观地和定量地评估新疗法在预防或去除每个患者的β淀粉样蛋白方面的功效。测试、用户界面评价和ADER报告生成实用程序和临床应用的重要部分将在德克萨斯州达拉斯UT西南医学中心核医学中心Michael Devous博士的监督下在子项目中进行。在纽黑文的MNI，我们将继续在我们的放射性示踪剂评估计划（RTEP）项目中测试和评估ADER，在该项目中，我们将继续测试潜在的新β淀粉样蛋白PET和SPECT成像剂，同时由我们的内部神经学家和支持人员对受试者进行临床评估。对社会的潜在益处是相当大的，因为ADER分析包将为阿尔茨海默病进展提供定量生物标志物分析方法，以获得个体化治疗效果。阿尔茨海默病（AD）与显著的发病率和有用的标记物和/或脑扫描分析包，如本建议的ADER，将增加我们对AD疾病进展的理解，并提供客观的评估神经保护和恢复治疗。这种完全自动化的图像处理还将允许在使用新的PET和SPECT放射性配体的临床试验中研究更少的受试者（具有相同的临床功效）。随着新的示踪剂和疗法的开发，ADER将与这些研究共同发展成为一种用于诊断、分期和治疗阿尔茨海默病的优化图像分析方法。